Artiva said it will quit its autoimmune cell-therapy program and cut staffing after reports of patient deaths, making it the third company recently to disclose fatal events in an autoimmune cell therapy trial. The disclosure underscores the elevated safety scrutiny facing cell therapies entering or expanding clinical development in immune-mediated diseases. The report notes that Artiva’s decision follows similar fatal-event announcements from other companies, highlighting how emerging efficacy signals can collide with adverse outcomes in early-to-mid-stage studies. Workforce reductions point to near-term pressure on trial continuity and corporate runway. For biotech operators, the development is a reminder that autoimmune cell-therapy programs can face rapidly escalating risk management and regulatory actions once serious safety events occur. Patients and clinicians may see slower timelines for similar approaches as companies pause, re-evaluate protocols, and work through safety review processes.